Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipatasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 known ✓ | Q9Y243 | 20/20 | 1.00 |
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | PRKG1 | Q13976 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipatasertib SCHEMBL191659 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL31658211 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29881570 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL17424852 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191491 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191495 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191492 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191496 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL19867534 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL27128127 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2202 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4719399-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND AKT INHIBITORS | Arvinas Operations, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| WO-2022079031-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | claimed |
| WO-2022078566-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | claimed |
| WO-2022081923-A2 | SYSTEMS FOR AND METHODS OF TREATMENT SELECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220033775-A1 | EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. | 2022-02-03 | — | — | US | claimed |
| WO-2022017524-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳晶泰科技有限公司 | 2022-01-27 | — | — | WO | claimed |